Lung Cancer | Age 81 | New Dx
81yo man with stage IIIB RLL adenocarcinoma. The mass is 11.5 cm. Radiation oncology wants me to shrink it before they attempt radiation, so I would plan to treat him as unresectable/advanced/metastatic with carbo/pem/pem. However, due to the carbo shortage I need to find an alternative. Any other recommendations for systemic therapy?
Read ResponseClassical Hematology | Age 40 | New Dx
Classical Hematology Specialist
Middle age female on long term apixaban for DVT in 2017. She has been stable without evidence of recurrence. She is admitted in 2023 with bacteremia. Has a femoral PICC in place for antibiotic access and a week later develops catheter associated femoral vein DVT. How do you manage her new PICC associate DVT?
Read ResponseHodgkin Lymphoma | Age 31 | R/R
Hodgkin Lymphoma Specialist
Patient has a heavily treated history of nodular sclerosing HL refractory to several lines of treatment. His current regimen on pembrolizumab has been discontinued due to manifesting with severe recurrent pancreatitis and arthralgias believed to be immunotherapy toxicity-related. Are there any other options to treat in this patient, acknowledging he wants continued aggressive treatment given his age?
Read ResponseGI Cancer | Age 86 | New Dx
86 yr male with pT3N1b moderately diff sigmoid colon adenoca. PS 0. MLH1 and PMS2 deficient. Should that result impact his therapy or since his tumor is dMMR offer xeloda +/- oxaliplatin? Have you used half dose oxali per FOCUS2 data?
Read ResponseClassical Hematology
Classical Hematology Specialist
27yr old referred to me for menorrhagia from Gyn after FVIII activity came back at 39%. VWF panel normal. Bleeding score 1. I'm having trouble getting Hemophilia genetic testing done. She would also like to know for future conception purposes. In the interim would you recommend tranexamic acid for her?
Read ResponseCLL | Age 63 | New Dx
63 y/o female with HTN, HLD and good PS presenting with adenopathy and B symptoms with thrombocytopenia and anemia. Diagnosed with poor risk CLL with 17p del. How do you choose frontline therapy? Is zanubrutinib a good option?
Read Response